brand names of glp 1 drugs glp-1 receptor agonist Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Report Market Overview: GLP-1 Agonists and

So, GLP-1s lead to clinically significant weight loss rarely observed in intervention trials that use lifestyle interventions without medications

Cardiovascular disease The impact of GLP-1RAs on major cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) has been assessed

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Philippe J

To the best of our knowledge, this meta-analysis is the first to evaluate the effects and safety of SGLT2i and GLP-1RAs as first-line therapy for T2DM with low cardiovascular risk

Dillon JS, Tanizawa Y, Wheeler MB, Leng XH, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, and Boyd AE, 3rd

Tirzepatide, administered as a weekly subcutaneous injection, and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings